- Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”) are shifting the odds through rational design.
- Six new antisense drugs gained FDA approval in 2023–2024, bringing total approvals above 20; evidence of accelerating regulatory momentum.
- Oncotelic Therapeutics’ OT-101 (Trabedersen) is the only TGF-β2-specific antisense in Phase 3 trials, targeting pancreatic cancer and other resistant malignancies.
The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates fall to just 3%. These economics have created a bottleneck that leaves patients waiting years for new treatments that rarely arrive.
Antisense oligonucleotides, short synthetic strands of DNA or RNA that silence disease-causing genes, are beginning to rewrite those odds. With six new FDA approvals since 2023 and more than 50 candidates in active trials, ASOs are experiencing a long-anticipated breakout. Oncotelic Therapeutics Inc. (OTCQB: OTLC) aims to be at the forefront with OT-101 (Trabedersen), the only TGF-β2-specific antisense therapy…
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
